Yechen Wu1, Xi Chen2, Duocheng Qian3, Wei Wang2, Yiping Zhang1, Jinxin Hu1, Jun Zhu1, Qiang Wu4, Tinghu Cao5. 1. Department of Urology, Baoshan Branch, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201900, People's Republic of China. 2. Department of Urology, Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, People's Republic of China. 3. Department of Urology, Shanghai Forth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, 200434, People's Republic of China. 4. Department of Urology, Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, People's Republic of China. qiang_wu0988@163.com. 5. Department of Urology, Baoshan Branch, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201900, People's Republic of China. tinghu_cao@126.com.
Abstract
BACKGROUND: A history of prior cancer commonly results in exclusion from cancer clinical trials. However, whether a prior cancer history has an adversely impact on clinical outcomes for patients with advanced prostate cancer (APC) remains largely unknown. We therefore aimed to investigate the impact of prior cancer history on these patients. METHODS: We identified patients with advanced prostate cancer diagnosed from 2004 to 2010 in the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was used to balance baseline characteristics. Kaplan-Meier method and the Cox proportional hazard model were utilized for survival analysis. RESULTS: A total of 19,772 eligible APC patients were included, of whom 887 (4.5 %) had a history of prior cancer. Urinary bladder (19 %), colon and cecum (16 %), melanoma of the skin (9 %) malignancies, and non-hodgkin lymphoma (9 %) were the most common types of prior cancer. Patients with a history of prior cancer had slightly inferior overall survival (OS) (AHR = 1.13; 95 % CI [1.02-1.26]; P = 0.017) as compared with that of patients without a prior cancer diagnosis. Subgroup analysis further indicated that a history of prior cancer didn't adversely impact patients' clinical outcomes, except in patients with a prior cancer diagnosed within 2 years, at advanced stage, or originating from specific sites, including bladder, colon and cecum, or lung and bronchus, or prior chronic lymphocytic leukemia. CONCLUSIONS: A large proportion of APC patients with a prior cancer history had non-inferior survival to that of patients without a prior cancer diagnosis. These patients may be candidates for relevant cancer trials.
BACKGROUND: A history of prior cancer commonly results in exclusion from cancer clinical trials. However, whether a prior cancer history has an adversely impact on clinical outcomes for patients with advanced prostate cancer (APC) remains largely unknown. We therefore aimed to investigate the impact of prior cancer history on these patients. METHODS: We identified patients with advanced prostate cancer diagnosed from 2004 to 2010 in the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was used to balance baseline characteristics. Kaplan-Meier method and the Cox proportional hazard model were utilized for survival analysis. RESULTS: A total of 19,772 eligible APCpatients were included, of whom 887 (4.5 %) had a history of prior cancer. Urinary bladder (19 %), colon and cecum (16 %), melanoma of the skin (9 %) malignancies, and non-hodgkin lymphoma (9 %) were the most common types of prior cancer. Patients with a history of prior cancer had slightly inferior overall survival (OS) (AHR = 1.13; 95 % CI [1.02-1.26]; P = 0.017) as compared with that of patients without a prior cancer diagnosis. Subgroup analysis further indicated that a history of prior cancer didn't adversely impact patients' clinical outcomes, except in patients with a prior cancer diagnosed within 2 years, at advanced stage, or originating from specific sites, including bladder, colon and cecum, or lung and bronchus, or prior chronic lymphocytic leukemia. CONCLUSIONS: A large proportion of APCpatients with a prior cancer history had non-inferior survival to that of patients without a prior cancer diagnosis. These patients may be candidates for relevant cancer trials.
Authors: Janet S de Moor; Angela B Mariotto; Carla Parry; Catherine M Alfano; Lynne Padgett; Erin E Kent; Laura Forsythe; Steve Scoppa; Mark Hachey; Julia H Rowland Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-27 Impact factor: 4.254
Authors: Marie E Wood; Victor Vogel; Andrea Ng; Lewis Foxhall; Pamela Goodwin; Lois B Travis Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Caijin Lin; Jiayi Wu; Shuning Ding; Chihwan Goh; Lisa Andriani; Kunwei Shen; Li Zhu Journal: Cancer Res Treat Date: 2019-11-18 Impact factor: 4.679